Greater use of ESAs and iron at lower hematocrit levels decrease risk of death for hemodialysis patients

Links shared publicly online about this topic.

1,342
total visits

Greater use of ESAs and iron at lower hematocrit levels decrease risk of death for hemodialysis patients

Greater use of erythropoiesis-stimulating agents (ESAs) and more frequent use of iron at lower hematocrit levels (the proportion of the blood that consists of red blood cells) was associated with a decreased risk of death for hemodialysis patients, according to a study in the March 3 issue of JAMA.

View full resource at news-medical.net

Tags: Dialysis